The FDA approval of Pfizer's Talzenna in combination with Xtandi for the treatment of homologous recombination repair gene-mutated metastatic castration-resistant prostate cancer is a positive development for the company. This approval could lead to increased sales and revenue for Pfizer, as it expands the potential market for Talzenna. The news is highly relevant to Pfizer and important for investors, as it could impact the company's financial performance.